Skip to main content
51°
Partly Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Business Service Directory
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
89bio, Inc. - Common Stock
(NQ:
ETNB
)
6.060
+0.170 (+2.89%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 17, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about 89bio, Inc. - Common Stock
< Previous
1
2
3
Next >
89bio to Participate in the Leerink Partners Global Healthcare Conference
March 03, 2025
From
89bio, Inc.
Via
GlobeNewswire
89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
February 27, 2025
From
89bio, Inc.
Via
GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 06, 2025
From
89bio, Inc.
Via
GlobeNewswire
89bio Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 03, 2025
From
89bio, Inc.
Via
GlobeNewswire
89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants
January 28, 2025
From
89bio, Inc.
Via
GlobeNewswire
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
January 27, 2025
From
89bio, Inc.
Via
GlobeNewswire
89bio Provides Business Update and Outlook for 2025
January 13, 2025
From
89bio, Inc.
Via
GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 19, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 29, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio to Participate in the 7th Annual Evercore HealthCONx Conference
November 26, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024
November 15, 2024
New post-hoc analyses reinforce pegozafermin’s potential anti-fibrotic effects and the potential utility of non-invasive tests which correlate to histological endpoints
From
89bio, Inc.
Via
GlobeNewswire
89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants
November 12, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
November 12, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Reports Third Quarter 2024 Financial Results and Corporate Updates
November 07, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio to Participate in the UBS Global Healthcare Conference
November 05, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024
October 15, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 11, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference
September 30, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 19, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer
September 16, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio to Participate in Upcoming Investor Conferences
August 29, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 09, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Appoints Francis Sarena as Chief Operating Officer
August 07, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Reports Second Quarter 2024 Financial Results and Corporate Updates
August 05, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Appoints Charles McWherter, Ph.D., to its Board of Directors
August 05, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 12, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 14, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress
May 22, 2024
-Poster presentation selected for the EASL Poster Tour, a dedicated discussion session-
From
89bio, Inc.
Via
GlobeNewswire
89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis
May 14, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 10, 2024
From
89bio, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
